OncoMatch/Clinical Trials/NCT06911008
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Official title: Phase I Trial of SCD I: A First in Human Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of MTI-301 in Patients With Advanced Malignancy
Is NCT06911008 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies SCD1 Inhibitor MTI-301 for metastatic malignant solid neoplasm.
Treatment: SCD1 Inhibitor MTI-301 — This phase I trial tests the safety, side effects, and best dose of MTI-301 in treating patients with solid cancers that have spread from where they first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and that have not responded to previous treatment (refractory). MTI-301 is a drug that inhibits an enzyme called SCD1. SCD1 is an enzyme that promotes tumor growth and spread and is upregulated in some cancer types. MTI-301 may disrupt the activity of SCD1, which may lead to reduced tumor growth and/or spread.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard-of-care therapy
refractory to or intolerant of existing, standard-of-care therapy(ies), known to provide clinical benefit for their condition
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; ANC ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3
Kidney function
Calculated creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's syndrome); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement)
Hemoglobin ≥ 9.0 g/dL... ANC ≥ 1500/mm^3... Platelet count ≥ 100,000/mm^3... Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's syndrome)... ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement)... Calculated creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06911008 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard-of-care therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify